Delving into the Latest Updates on Micafungin Sodium with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide, Cyclic Peptide

Synonyms

MICAFUNGIN, Micafungin sodium (JAN/USAN), Micamin

+ [6]

Target

1,3-beta-glucan synthase

Action

inhibitors

Mechanism

1,3-beta-glucan synthase inhibitors, Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersHemic and Lymphatic Diseases+ [1]

Active Indication

AbscessCandida peritonitisSystemic Candidiasis+ [7]

Inactive Indication

acute leukemiaCandidiasis, OralInvasive aspergillosis+ [2]

Originator Organization

Astellas Pharma, Inc.

Active Organization

Sandoz Pharmaceuticals AGYuhan Corp.Astellas Pharma Australia Pty Ltd.

+ [7]

Inactive Organization

Astellas Pharma Global Development, Inc.Astellas Pharma US, Inc.Teva Pharmaceuticals USA, Inc.

License Organization

Sandoz International GmbHSandoz AG

Astellas Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (08 Oct 2002),

AspergillosisCandidiasis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC56H71N9NaO23S

InChIKeyPWAXVQURCGJSNE-WZPXRXMFSA-N

CAS Registry208538-73-2

Sequence Code 524728241

Febrile neutropenia is often seen in patients with hematologic malignancies who receive cytotoxic chemotherapy. These patients are usually placed on posaconazole prophylaxis upon starting chemotherapy. If an episode of febrile neutropenia occurs, generally an anti-pseudomonal beta lactam, like cefepime or piperacillin-tazobactam, is initiated. In patients who continue to fever on these agents, the optimal method of antimicrobial revision has yet to be determined.

Start Date01 Aug 2024

Sponsor / Collaborator

Wake Forest School of Medicine

NCT06413056

/ CompletedPhase 4IIT

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial

The incidence of fungal infection has increased dramatically over the past few decades.This is due to increase in survival rates of preterm neonates, advances in medical technology and drug therapy, broad spectrum antibiotics and parenteral nutrition . The resistance to antifungal agents has increased. This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture.

Start Date20 Oct 2022

Sponsor / Collaborator

Ain Shams University

100 Clinical Results associated with Micafungin Sodium

Login to view more data

100 Translational Medicine associated with Micafungin Sodium

Login to view more data

100 Patents (Medical) associated with Micafungin Sodium

Login to view more data

2,052

Literatures (Medical) associated with Micafungin Sodium

01 Dec 2026·Virulence

Micafungin microevolution in Candida auris reveals resistance development without in vivo fitness compromise.

Article

Author: Papp, Csaba ; Bohner, Flora ; Gácser, Attila ; Veres, Éva ; Szilovics, Zora ; Nosanchuk, Joshua D

Candida auris is an emerging multidrug-resistant pathogen with high transmissibility in healthcare settings. Although echinocandin resistance in Candida is typically associated with fitness loss, we found that micafungin-resistant C. auris strains (MICA^evo) generated from two distinct source isolates (AR0381 and AR0387) via experimental microevolution retained full virulence. Evolved strains developed stable resistance to multiple echinocandins, while AR0387 (B8441), originating from MICA^evo strain, also acquired increased azole tolerance. Whole-genome sequencing revealed clinically relevant mutations in FKS1, as well as changes in genes involved in ergosterol biosynthesis (ERG3), amino acid metabolism, and PKA signaling. Despite in vitro sensitivity to cell wall stressors, resistant strains maintained or even enhanced colonization in a murine systemic infection model. Independently evolved strains showed similar antifungal resistance profiles, and although minor differences of pathogenic potential were noted, no consistent virulence attenuation was observed, indicating the reproducibility of phenotype changes. These findings suggest that C. auris can acquire echinocandin resistance without compromising pathogenicity, supporting its persistence and spread in clinical settings.

01 Aug 2026·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparative efficacy and safety of antifungal prophylactic agents in allogeneic hematopoietic stem cell transplantation: A systematic review and network meta-analysis

Review

Author: Fan, Yuping ; Chen, Xin ; Li, Xinyi ; Shao, Ruonan ; Zhang, Tingting ; Feng, Sizhou

BACKGROUND:

Invasive fungal infections remain a major cause of morbidity and mortality among allogeneic hematopoietic stem cell transplantation recipients. There is still limited high-quality comparative evidence for antifungal agents.

METHODS:

We conducted a systematic review and network meta-analysis of randomized controlled trials and observational studies (PROSPERO: CRD420251270033), with databases search updated to September 2025. A prespecified assumption-based proportional imputation method was applied to estimate outcomes in mixed populations. Relative risks (RRs) were synthesized using a frequentist random-effects model, and treatments were ranked using surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-two studies were selected, including 10 006 hematopoietic stem cell transplantation recipients. Across randomized controlled trials, posaconazole (RR, 0.19; 95% confidence interval, 0.08-0.44) and voriconazole (RR, 0.20; 95% confidence interval, 0.09-0.42) demonstrated the strongest efficacy against invasive fungal infections compared with placebo. Posaconazole ranked first for preventing invasive aspergillosis (SUCRA, 77.1%) and fungus-related mortality (SUCRA, 91.9%), while micafungin had the lowest discontinuation risk (SUCRA, 95.5%). Observational data favoured posaconazole tablets (SUCRA, 90.3%) over suspension (SUCRA, 75.2%). Isavuconazole showed lower hepatotoxicity-related discontinuation (5.3% vs. 22.9%; P = 0.0002), though these findings are based on limited cases. Trials implementing therapeutic drug monitoring showed a non-significant trend towards improved efficacy.

CONCLUSIONS:

Posaconazole and voriconazole demonstrate strong efficacy. Posaconazole tablets offer a favourable balance between benefit and risk. However, the potential safety benefits of isavuconazole warrant further evidence accumulation.

01 Jun 2026·Exploratory research in clinical and social pharmacy

Physicochemical compatibility and stability of ketamine co-administered with selected supportive care drugs and parenteral nutrition in pediatric oncology

Article

Author: Sunderland, Bruce ; Isaac, Emily ; Varonen, Katriina ; Luna, Giuseppe ; Czarniak, Petra ; Soggee, Johnathan ; Martinez, Jorge

Purpose:

Ketamine has been previously administered as an anesthetic but recently gained importance as an analgesic in pediatric oncology. Despite its efficacy, continuous intravenous administration to children with cancer is interrupted when other essential drugs require infusion. This occurs because its compatibility with many drugs and lipid emulsions is unknown, causing inadequate pain management and patient discomfort. This study has assessed the physicochemical compatibility and stability of ketamine with selected drugs, based on usage frequency data, and lipid emulsion formulations administered to pediatric cancer patients at tertiary hospitals.

Methods:

Physicochemical compatibility of ketamine involved admixture with selected concentrations of drugs, for physical incompatibility. Admixtures of ketamine with lipid emulsions and the other drugs included determining ketamine's chemical concentration using high performance liquid chromatography (HPLC). Particle size analysis investigated lipid stability.

Results:

The HPLC assay was linear over a range of concentrations (0.05 mg/mL - 0.5 mg/mL), validated under forced degradation conditions causing no interferences and an intra- and inter-day precision less than 2%. Ketamine was highly stable with all drugs and lipid emulsions tested, retaining >90% of its concentration for all systems investigated for two hours. No additional physical incompatibility occurred., but amoxicillin incompatibility was confirmed. Lipid emulsion stability was maintained, with no system exceeding particle size limits.

Conclusions:

Ketamine is safe to co-administer with AmBisome®, cyclizine, hydromorphone, Intralipid®, magnesium sulfate, metoclopramide, micafungin, potassium dihydrogen phosphate, sodium dihydrogen phosphate and vancomycin. Our findings are significant for improving pain management in vulnerable patients simultaneously administered the tested drugs with ketamine.

29

News (Medical) associated with Micafungin Sodium

04 Sep 2025

·www.globenewswire.com

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2025 JERSEY CITY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced multiple upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the upcoming 12th Congress on Trends in Medical Mycology (TIMM-12), which is scheduled to take place from September 19th to 22nd, 2025, in Bilbao, Spain. “Our six presentations at this year’s TIMM-12 Congress highlight the significant potential of SCY-247 to combat difficult, resistant Candida infections, including C. auris,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “We are developing SCY-247 to specifically address one of the most serious and challenging issues in infectious disease, and the data from these presentations provide highly encouraging evidence that SCY-247 has the potential to address these difficult-to-treat and life-threatening fungal infections. Later this quarter, we anticipate reporting results from our Phase 1 SAD/MAD trial of SCY-247, which represents an important next step in further advancing this exciting program.” SCY-247 data presentations at TIMM-12: TitleSCY-247, a Novel Second-Generation IV/Oral Triterpenoid Antifungal, Demonstrates In vitro Activity against C. auris, including the majority of FKS1 mutants Session:Oral Presentation, S15.5S Session Date:Saturday, September 20, 2025 Presentation Start Time17:25 Central European Time (CET) (10 minutes) Presenting AuthorEelco Meijer, MD, PhDAffiliations: Canisius-wilhelmina Hospital (CWZ)/Dicoon, Radboudumc-CWZ Center of Expertise for Mycology Summary:Candida auris is a public health concern causing large and persistent outbreaks in healthcare institutions, globally. High incidence of resistance to approved antifungals necessitates investigation of novel drugs for future patient care. Here, we performed antifungal susceptibility testing on the investigational compound SCY-247 and other antifungals, including echinocandins anidulafungin and micafungin against 65 unique FKS1 resistant C. auris isolates representing clades I, II, III, IV, and V. Overall, in comparison to the echinocandins, SCY-247 consistently demonstrated lower MICs for C. auris in isolates with commonly found FKS1 resistance mutations. TitleThree Months of SCY-247 EUCAST MIC Testing: Uniform Activity Against Candida Species and No Cross-Resistance to Echinocandins Poster #P052 Session DateSunday, 21 September 2025 Presentation Start Time11:15 CET (30 minutes) Presenting AuthorKarin Meinike Jørgensen PhDAffiliations: Statens Serum Institut SummaryWe present the first three months of EUCAST SCY-247 MICs compared to anidulafungin and micafungin MICs of 293 Candida isolates. SCY-247 displayed uniform activity against all Candida species included, with no indication of cross-resistance to the echinocandins. TitleIn vitro efficacy of second-generation triterpenoid antifungal, SCY-247 against multidrug- and pandrug-resistant Candida auris Poster #P053 Session DateSaturday, 20 September 2025 Presentation Start Time11:15 CET (30 minutes) Presenting AuthorVishnu Chaturvedi, PhDAffiliations: New York Medical College, Valhalla, New York Summary:Candida auris is a newly recognized global health threat by the CDC and WHO. In the USA, the New York –New Jersey metropolitan area remains a hotbed for multidrug- and pandrug-resistant C. auris strains. 300 C. auris isolates, mostly from New York area, were tested against SCY-247 and 10 other antifungal agents. SCY-247 demonstrated potent activity against C. auris including pandrug-resistant isolates. TitleThe Novel Second-Generation IV/Oral Triterpenoid SCY-247 Maintains In vitro and In vivo Activity against Resistant Candida glabrata Poster #P423 Session DateSaturday, 20 September 2025 Presentation Start Time11:15 CET (30 minutes) Presenting AuthorNathan Wiederhold, PhDAffiliations: University of Texas Health Science Center at San Antonio SummaryCandida glabrata is a major cause of invasive candidiasis and is considered a high priority pathogen by the WHO. In vitro susceptibility testing was performed against 29 echinocandin-resistant clinical strains of C. glabrata. SCY-247 maintained in vitro activity against echinocandin-resistant C. glabrata and also demonstrated in vivo efficacy in an invasive candidiasis mice model caused by an echinocandin- and fluconazole-resistant C. glabrata strain. TitleEfficacy of once or twice daily oral SCY-247, a second-generation triterpenoid antifungal, in a murine model of Candida auris infection Poster #P426 ThemeNew antifungal agents Session DateSunday, 21 September 2025 Presentation Start Time11:15 CET (30 minutes) Presenting AuthorMahmoud Ghannoum, PhDAffiliations: Case Western Reserve University and University Hospitals Cleveland Medical Center SummaryCandida auris is a multidrug resistant fungus exhibiting a 200% increase in incidence in the U.S from 2019 to 2023. The objective was to assess the activity of 7 days of once or twice daily oral SCY-247 treatment in lowering kidney fungal burden in a mouse model of C. auris infection. SCY-247 demonstrated in vivo efficacy against invasive C. auris candidiasis. Significant reductions in fungal burden were observed in the kidneys of mice treated with SCY-247 in a dose dependent fashion with similar activity observed between QD and BID doses. TitleIn vitro activity of SCY-247 and comparators against clinical isolates of Aspergillus spp. and Lomentospora prolificans Poster #P427 ThemeNew Antifungal Agents Session DateSaturday, 20 September 2025 Presentation Start Time11:15 CET (30 minutes) Presenting AuthorAnastasiia HrynzovskaAffiliations: Mycology Reference Laboratory, National Centre for Mycology, Bogomolets National Medical University SummaryThe aim of this study is to investigate the in vitro activity of SCY-247 against cryptic Aspergillus species and Lomentospora prolificans isolated from clinical samples. A total of 54 clinical isolates were analyzed including cryptic species of Aspergillus (n=48) and Lomentospora prolificans (n=6). SCY-247 activity was compared to 3 marketed antifungals. SCY-247 exhibited low MECs against cryptic Aspergillus species and moderately high MECs against L.prolificans. About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com. Forward-Looking Statements Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: Company anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3, 2025. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT:Investor RelationsIrina KofflerLifeSci AdvisorsTel: 917-734-7387ikoffler@lifesciadvisors.com

Phase 1Drug ApprovalClinical Result

19 Aug 2025

·www.prnewswire.com

Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)

MAHWAH, N.J., Aug. 19, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA – 021506 and the company will begin distribution in September 2025. According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market3 achieved annual sales of approximately $60.7 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need." 1 Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication(s) listed in Glenmark's approved label. 2 All brand names and trademarks are the property of their respective owners. 3 Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications. *IQVIA® National Sales Perspectives: Retail & Non-Retail, June 2025 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3 million lives over the last decade through its CSR interventions. For more information, visit . You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma). Logo: SOURCE Glenmark Pharmaceuticals Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

19 Aug 2025

·pharma.economictimes.indiatimes.com

Glenmark to Launch antifungal drug Micafungin' in US

New Jersey : Glenmark Pharmaceuticals Inc, USA, a wholly owned subsidiary of Mumbai based Glenmark Pharmaceuticals, announced plans to launch Micafungin , an antifungal medication, in the US market. The product is the therapeutic equivalent of the reference listed drug Mycamine , marketed by Astellas Pharma . According to IQVIA data, Micafungin estimated moving annual turnover (MAT) in the US stood at $60.7 million (over Rs 500 crore). “We are excited to announce the launch of Micafungin, which will expand our institutional channel portfolio,” said Marc Kikuchi, President & Business Head – North America, Glenmark Pharmaceuticals. As per the company release, Glenmark will market the drug in single-dose vials and will begin distribution in September 2025. By Online Bureau ,

Drug Approval

100 Deals associated with Micafungin Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02465	Micafungin Sodium	J02AX05	DB01141

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Systemic Candidiasis	United States	Ph Healthcare Services	16 Jun 2021
Neutropenia	Australia	Astellas Pharma Australia Pty Ltd.	08 May 2013
Candidiasis, Invasive	European Union	Sandoz Pharmaceuticals AG	25 Apr 2008
Candidiasis, Invasive	Iceland	Sandoz Pharmaceuticals AG	25 Apr 2008
Candidiasis, Invasive	Liechtenstein	Sandoz Pharmaceuticals AG	25 Apr 2008
Candidiasis, Invasive	Norway	Sandoz Pharmaceuticals AG	25 Apr 2008
Abscess	United States	Astellas Pharma US, Inc.	22 Jan 2008
Candida peritonitis	United States	Astellas Pharma US, Inc.	22 Jan 2008
Candidemia	South Korea	Yuhan Corp.	25 Oct 2006
Candidiasis of the esophagus	South Korea	Yuhan Corp.	25 Oct 2006
Mycoses	South Korea	Yuhan Corp.	25 Oct 2006
Aspergillosis	Japan	Astellas Pharma Co. Ltd.	08 Oct 2002
Candidiasis	Japan	Astellas Pharma, Inc.	08 Oct 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fungemia	Phase 3	China	Astellas Pharma, Inc.	01 Nov 2008
Candidiasis, Oral	Phase 3	Brazil	Astellas Pharma, Inc.	01 Aug 2003
Candidiasis, Oral	Phase 3	Peru	Astellas Pharma, Inc.	01 Aug 2003
Candidiasis, Oral	Phase 3	South Africa	Astellas Pharma, Inc.	01 Aug 2003
Invasive Fungal Infections	Phase 3	United States	Astellas Pharma, Inc.	01 Jan 2003
Invasive Fungal Infections	Phase 3	Canada	Astellas Pharma, Inc.	01 Jan 2003
acute leukemia	Phase 2	-	Astellas Pharma, Inc.	19 Sep 2015
Invasive aspergillosis	Phase 2	Austria	Astellas Pharma, Inc.	29 Jan 1999
Invasive aspergillosis	Phase 2	France	Astellas Pharma, Inc.	29 Jan 1999
Invasive aspergillosis	Phase 2	Germany	Astellas Pharma, Inc.	29 Jan 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06413056 (Pubmed \| Ital J Pediatr)	Phase 4	Invasive Fungal Infections	56	Micafungin	btgekbhlsi(advxcdmivz) = There was an increase in blood urea nitrogen with Amphotericin B nrlfakxkru (ciprzdcpvb ) View more	Positive	27 Feb 2025
NCT03421002 (Pubmed \| Antimicrob Agents Chemother) Manual	Phase 2	Candidiasis, Invasive	35	Micafungin	fyxdbijmne(kgcgtkycft) = xgtptrvjpm ylfofdidxo (ighlberaot )	Positive	18 Mar 2021
NCT01090141 (Micafungin, CTgov)	Phase 4	Obesity	36	Micafungin (Subjects Recieving 100 mg of Micafungin)	eraauvnpjm(omtilaeoka) = erelwioutg larrgrdcdq (iaslmredus, dlnuhnlvbd - pgkyoaljud) View more	-	27 Nov 2020
				Micafungin (Subjects Recieving 300 mg of Micafungin)	eraauvnpjm(omtilaeoka) = tfznvuzhog larrgrdcdq (iaslmredus, kmawtpcqhd - ejcxhddvcw) View more
NCT01974375 (Pubmed \| J Gastrointest Surg)	Phase 3	-	172	Micafungin	uacsnfnrti(bjlqipefjp) = A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. qqtxenknft (qgwogzfgis )	Positive	01 Apr 2020
				Fluconazole
Tandem Meetings ASTCT and CIBMTR2020	Not Applicable	Hematopoietic stem cell transplantation	-	Micafungin for PAP	vgnnmeybvh(joqhhpxhgf) = approximately 8% nbnoaxrpyk (fovyhofsju ) View more	-	01 Mar 2020
NCT03102658 (Pubmed \| J Antimicrob Chemother)	Phase 4	Obesity, Morbid	24	micafungin (Normal-weight healthy subjects)	jqcmtttikl(mbtercdfzk) = dvrwhepotf ofcirdnkmi (hwqchqkcvk ) View more	-	01 Apr 2019
				micafungin (Obese healthy subjects)	jqcmtttikl(mbtercdfzk) = pkffzjrqjt ofcirdnkmi (hwqchqkcvk ) View more
EUCTR2012-004008-37-IT (EBMT2018)	Phase 2	acute leukemia	87	Micafungin	dignsmmono(ierfsutxzh) = qjznliziey taqhydjnri (ckiicgnlyt )	-	19 Nov 2018
				Placebo	dignsmmono(ierfsutxzh) = qgvuzwmvds taqhydjnri (ckiicgnlyt )
NCT02172768 (Pubmed \| J Antimicrob Chemother)	Phase 2	-	30	300 mg of micafungin twice weekly	nhkrujdeow(ejpqbonvfv) = lfikgywatc zhuulwwctp (rdfqmeyqwe, 485 - 717)	-	01 Nov 2018
				100 mg of micafungin once daily	nhkrujdeow(ejpqbonvfv) = mfjpfwozhp zhuulwwctp (rdfqmeyqwe, 583 - 829)
NCT00815516 (MAGIC-2, Pubmed) Manual	Phase 3	Candidiasis, Invasive	30	Micafungin	xfqbceuyfa(cjmolsymyz) = qzstrowawb okoycvdgxf (bgfsmhjldp, 36 - 81) View more	Similar	01 Oct 2018
				amphotericin B deoxycholate	xfqbceuyfa(cjmolsymyz) = jsgqboqqvh okoycvdgxf (bgfsmhjldp, 35 - 93)
NCT02678598 (Pubmed \| Adv Ther)	Not Applicable	Invasive Fungal Infections	2,555	Micafungin	dhhwvdnylj(asqsxkzrcn) = dgzqoxezih gfwaigdoqq (cvrfxxzpgg )	-	01 Sep 2018

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Micafungin Sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation